Companies & People
FDA grants Fast Track status to Liquidia’s YUTREPIA for new use
The FDA granted Fast Track designation to Morrisville-based Liquidia's YUTREPIA for an investigational use in systemic-sclerosis-associated Raynaud's phenomenon.